Quick Answer
CRISPR Therapeutics AG reported Diluted EPS of $6.47 per share (loss) for fiscal year 2025.
CRISPR Therapeutics AG Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$6.47 | -49.1% |
| 2024 | -$4.34 | -123.7% |
| 2023 | -$1.94 | +76.8% |
| 2022 | -$8.36 | -277.9% |
| 2021 | $4.70 | +188.8% |
| 2020 | -$5.29 | -552.1% |
| 2019 | $1.17 | +134.0% |
| 2018 | -$3.44 | -101.2% |
| 2017 | -$1.71 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.17 | -15.8% | +51.3% |
| June 30, 2025 | -$2.40 | -61.1% | -51.9% |
| March 31, 2025 | -$1.58 | -10.5% | -56.4% |
| September 30, 2024 | -$1.01 | +28.4% | +32.2% |
| June 30, 2024 | -$1.49 | -52.0% | -4.2% |
| March 31, 2024 | -$1.43 | -113.4% | -1.4% |
| September 30, 2023 | -$1.41 | +37.1% | -43.9% |
| June 30, 2023 | -$0.98 | +59.2% | -46.3% |
- CRISPR Therapeutics AG showed a decrease of -49.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2017–2025 period, CRISPR Therapeutics AG’s diluted eps has declined by 278.4% (from $1.71 per share (loss) to $6.47 per share (loss)).
- The most recent figure is from CRISPR Therapeutics AG’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: